Therefore, the contribution of platelet-derived TGFβ1 in mediating human IPF disease remains unknown, although global depletion of either platelets or TGFβ1 is not feasible therapeutic options for patients with IPF. This evidence concerns the gene TGFB1 and idiopathic interstitial pneumonia.